How is acute poststreptococcal glomerulonephritis (APSGN) prevented?

Updated: Dec 05, 2018
  • Author: Rajendra Bhimma, MBChB, MD, PhD, DCH (SA), FCP(Paeds)(SA), MMed(Natal); Chief Editor: Craig B Langman, MD  more...
  • Print

A vaccine targeted against group A streptococci will prevent both invasive disease and nonsuppurative complications. The current thrust of group A streptococcal vaccine research has been to target the M protein. [64] A 26-valent vaccine has been developed that targets the variable region of the M proteins of the most common rheumatogenic cocci. Unfortunately, no M protein from nephritogenic streptococci were included in the vaccine. In addition, the most common M protein types in the developing world differ from those of more developed countries, thus rendering the vaccine less efficacious. The most effective public health measure in the developing world is to improve hygiene and provide better housing conditions to avoid overcrowding. This offers the best hope for elimination of epidemic pyoderma and thus preventing APSGN.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!